Mirvetuximab soravtansine-gynx is deur die USFDA goedgekeur vir FRα-positiewe, platinum-weerstandige epiteel-ovarium-, fallopiese buis- of primêre peritoneale kanker
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, platinum-resistant epithelial ..
Kliniese proewe
MESO-CAR T-selle-terapie vir terugvallende en refraktêre epiteel-ovariumkanker
March 2023: Brief Summary: The purpose of this clinical trial is to find out if anti-MESO antigen receptor CAR T-cell therapy can be used to treat epithelial ovarian cancer that has come back or stopped responding to other..
mirvetuximab soravtansine-gyn
Mirvetuximab soravtansine-gynx kry versnelde goedkeuring vir FRα-positiewe, platinum-weerstandige epiteel-ovarium-, fallopiese buis- of peritoneale kanker
November 2022: For adult patients who have had one to three prior systemic treatment regimens and have folate receptor alpha (FR) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, the F..
Lancet, Mekinis, Tamoxifen, Trametinib
Nuwe behandeling geïdentifiseer vir laegraadse en sereuse eierstokkanker
May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy an..
Cytalux, NCT03180307, pafolacianine, Target Laboratories
Pafolacianine is goedgekeur vir die identifisering van kwaadaardige eierstokkanker letsels
Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, has been licenced by the Food and Drug Administration for adult patients with ovarian cancer as an adjuvant for interoperative detection of..
Niraparib
Niraparib behaal ongelooflike resultate vir eierstokkanker en borskanker
Borskanker en eierstokkanker As u 'n bors- en eierstokkankerpasiënt is, kom u agter dat u 'n kanker is van die BRCA1 / 2-mutasie nadat u die genetiese toets geslaag het, en u lewe is gered. Volgens die Global Oncolog ..
Acalabrutunib, Avelumab, CART-terapie, Dabrafanib, Kymriah, Nuutste dwelms, Midostaurien, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Nuutste middels in die behandeling van kanker
Julie 2021: Kyk na die nuutste medisyne in die behandeling van kanker. Elke jaar, nadat die proewe en ander belangrike faktore ondersoek is, keur die USFDA dwelms goed, en dus kan kankerpasiënte nou glo dat 'n genesing baie naby is. ..